BioView Ltd. (TASE:BIOV) has signed a commercial cooperation agreement with France's ScreenCell to integrate BioView's cancer scanning systems with ScreenCell's technology for the isolation of rare circulating tumor cells.
The combined solution will make possible the isolation and classification of a range of tumor cells, which the sensitivity of current technologies cannot identify, in order to facilitate diagnosis and the making of personalized medical decision about the best treatment.
BioView president and CEO Dr. Alan Schwebel said, "We see strong synergy in the collaboration of the two companies in providing a comprehensive solution for a range of clinical laboratory and circulating tumor cell research needs. BioView's scanners can identify cells and automatically distinguish between real tumor cells and other cells. When talking about billions of blood cells (the number of cells in a blood sample), the need for automated scanning and identification is critical."
BioView's share price rose 3.8% by mid-afternoon to NIS 2.16, giving a market cap of NIS 28 million.
Published by Globes [online], Israel business news - www.globes-online.com - on July 9, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012